Latest Phase II Data Bolster Cidara’s Antifungal
Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.
You may also be interested in...
Biotech says rezafungin should best existing echinocandin agents in treatment of Candida pathogen infections, while also offering needed prophylaxis improvements for leukemia and lymphoma patients.
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.
Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.